149 related articles for article (PubMed ID: 7812182)
1. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
2. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Adamson AL; Kenney SC
Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
[TBL] [Abstract][Full Text] [Related]
3. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
4. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
5. Viral and cellular factors influence the activity of the Epstein-Barr virus BCR2 and BWR1 promoters in cells of different phenotype.
Nilsson T; Sjöblom A; Masucci MG; Rymo L
Virology; 1993 Apr; 193(2):774-85. PubMed ID: 8384755
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
7. Position and orientation independent transactivation by c-Myc.
Packham G; Bello-Fernandez C; Cleveland JL
Cell Mol Biol Res; 1994; 40(7-8):699-706. PubMed ID: 7787888
[TBL] [Abstract][Full Text] [Related]
8. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Epstein-Barr virus BamHI-H divergent promoter by DNA methylation.
Nonkwelo CB; Long WK
Virology; 1993 Nov; 197(1):205-15. PubMed ID: 8212555
[TBL] [Abstract][Full Text] [Related]
10. Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle.
Evans TJ; Jacquemin MG; Farrell PJ
Virology; 1995 Feb; 206(2):866-77. PubMed ID: 7856099
[TBL] [Abstract][Full Text] [Related]
11. In situ RT-PCR detection of Epstein-Barr virus immediate-early transcripts in CD4+ and CD8+ T lymphocytes.
Guan M; Romano G; Henderson EE
Anticancer Res; 1998; 18(5A):3171-80. PubMed ID: 9858880
[TBL] [Abstract][Full Text] [Related]
12. Telomerase activation by Epstein-Barr virus latent membrane protein 1 is associated with c-Myc expression in human nasopharyngeal epithelial cells.
Yang J; Deng X; Deng L; Gu H; Fan W; Cao Y
J Exp Clin Cancer Res; 2004 Sep; 23(3):495-506. PubMed ID: 15595642
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
14. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
15. c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo.
Mautner J; Behrends U; Hörtnagel K; Brielmeier M; Hammerschmidt W; Strobl L; Bornkamm GW; Polack A
Oncogene; 1996 Mar; 12(6):1299-307. PubMed ID: 8649832
[TBL] [Abstract][Full Text] [Related]
16. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
17. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
18. Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1.
Roussel MF; Davis JN; Cleveland JL; Ghysdael J; Hiebert SW
Oncogene; 1994 Feb; 9(2):405-15. PubMed ID: 8290253
[TBL] [Abstract][Full Text] [Related]
19. Identification of a PDGF-responsive element in the murine c-myc gene.
Sacca R; Cochran BH
Oncogene; 1990 Oct; 5(10):1499-505. PubMed ID: 2250909
[TBL] [Abstract][Full Text] [Related]
20. The role of immunoglobulin kappa elements in c-myc activation.
Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A
Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]